USPTO Issues Notice Of Allowance To NovaDel's Oral Spray Drug Delivery Technology

Published: 05-Nov-2009

For the short-term treatment of insomnia characterised by difficulties with sleep initiation

NovaDel Pharma (NovaDel) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for claims under US Patent Application No 10/671,715, entitled; Buccal, Polar and Non-polar Spray Containing Zolpidem, which covers a method of treating insomnia by administering zolpidem to humans utilising NovaMist Oral Spray spray technology. Once issued, this patent will expire in 2018.

NovaDel's Zolpimist (zolpidem tartrate) 5mg and 10mg Oral Spray product is approved by the FDA for the short-term treatment of insomnia characterised by difficulties with sleep initiation.

Zolpimist is NovaDel's second product approved by the FDA that uses NovaDel's proprietary NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien, sedative hypnotic for the treatment of insomnia.

The company said that upon issuance of the application, the company is expected to have been granted nine patents in the US, three patents in Canada and 66 patents throughout Europe, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden and Switzerland.

No items to display

Tell your friend about this article